Institute for Cancer Research

 

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

 PublicationsDoctoral theses
 2016 so far 
201522021
201417625
201319727
201217518
201120122

Annual report 2015 (pdf format)

 

Latest news

Announcement:

Resources to PDT/PCI related research, 2017

 

The Norwegian Radium Hospital Research Foundation will also for 2017 distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research. In 2016 various research projects within this field were founded with a total of NOK 1,79 million. Employees at the Oslo University Hospital are welcome to apply.
The closing date for applications is February 28th, 2017.

 
 

Announcement: Nominating outstanding scientists, closing date March 1st:

Excellent Researcher Award and Early Career Award 2017

 
From the 2016 ceremony: Pål Aukrust (Excellent Researcher Award) flanked by Therese Seierstad og Espen Melum (both Early Career Awards)
From the 2016 ceremony: Pål Aukrust (Excellent Researcher Award) flanked by Therese Seierstad og Espen Melum (both Early Career Awards)

 Oslo University Hospital hereby announce research awards in the following two catagories for 2017:

  • Excellent Researcher Award (one prize, 300.000 NOK)
  • Early Career Award (two prizes of 150.000 NOK each)

The candidate must be employed by Oslo University Hospital or University of Oslo, and be a member of a research group at Oslo University Hospital/University of Oslo.

 
 

Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention

 
First author Nadja Katheder and senior author Tor Erik Rusten
First author Nadja Katheder and senior author Tor Erik Rusten

Nadja Katheder and collaborators in the lab of Tor Erik Rusten, the Department of Molecular Cell Biology, and CCB has published an article entitled "Microenvironmental autophagy supports tumor growth", in an advanced online publication 11th of January in the journal Nature (journal impact factor 41.46). 
It is known that transformed tumor cells rewire growth and metabolism to support their own growth. How these changes occur in animals, however are poorly understood. In the published study, Katheder and co-workers show how malignant tumors coerce neighboring microenvironmental cells to support their own growth.
The findings have been subject to news coverage by the Norwegian national broadcasting corporation (NRK).

 
 

Story picked up by Science Translational Medicine as "Editor's choice":

New insight into the origin of disseminated tumor cells in breast cancer published in Genome Biology

 
Elen K. Møller, joint first author
Elen K. Møller, joint first author

Elen Kristine Møller, postdoc at the Department of Cancer Genetics, studied during her PhD project the fate of disseminated tumor cells (DTCs). In a collaborative study among OUS, University of Chicago, University of Leuven and the Francis Crick Institute it is revealed that breast cancer cells break away and spread to other parts of the body relatively late on in breast tumor development.
The findings are published in the December 9th issue of Genome Biology (journal impact factor 11.3), in an article entitled "Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing".

Update: The story has become the "Editors Choice" in the January 4th issue of Science Translational Medicine

 
 

Commentary article from Arne Klungland in Nature Methods on epitranscriptome analysis

 
Arne Klungland
Arne Klungland

In the Nature Methods (journal impact factor 25.3) January 2017 issue “Epitranscriptome analysis” is presented as the method of the year. In recent years, it has become clear that RNA molecules, including mRNAs, can be dynamically modified. Thus, this allows for a new strategy for gene regulation with vital biological consequences. Epitranscriptome analysis relates to methods that can profile RNA modifications in a sequence specific manner. In a commentary to this discovery, Klungland and co-workers from Department of Microbiology and Department of Gynecology, OUS, discuss the role of such modifications for the maturation of sperm and egg (meiosis) and pluripotent cells.

 
 

New knowledge about Wee1 and Chk1 inhibitors revealed by a flow cytometry-based compound screen

 
1st author Sissel Hauge and 2nd author Christian Naucke
1st author Sissel Hauge and 2nd author Christian Naucke

In a new study published in Oncotarget, Hauge et al. found an explanation for why combined inhibition of Chk1 and Wee1 gives synergistic anti-cancer effects.

Inhibitors of Wee1 and Chk1 kinases are currently in clinical trials in combination with radiation- or chemotherapy, due to their roles in inhibition of cell cycle checkpoints and DNA repair. Recent preclinical studies have shown synergistic effects of simultaneous Wee1 and Chk1 inhibition, but the mechanisms behind this synergy were not known.